Latest & greatest articles for ropinirole

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ropinirole or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ropinirole and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for ropinirole

1. A comparison of gabapentin enacarbil, ropinirole, pramipexole, and rotigotine for restless legs syndrome: a network meta-analysis

A comparison of gabapentin enacarbil, ropinirole, pramipexole, and rotigotine for restless legs syndrome: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

2. Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Full Text available with Trip Pro

Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Evidence suggests the potential to improve motor status in patients with stroke by modifying brain catecholaminergic tone. The current study hypothesized that increased dopaminergic tone via the dopamine agonist ropinirole, when combined with physiotherapy (PT), would significantly and safely increase gait velocity.Patients with moderate motor deficits due to stroke 1 to 12 months prior were randomized (double (...) blinded) to 9 weeks of immediate-release ropinirole or placebo, each with PT, and followed up for 3 additional weeks. Drug dose (0.25 to 4 mg once daily) was titrated weekly, as tolerated. The primary end point was gait velocity during the 12 weeks of study participation.Patients in the ropinirole+PT group averaged 2.4 mg/d by end of week 9, although the target dose was at least 3 mg/d. Ropinirole+PT was generally safe and well tolerated, including no drug-related serious adverse events. Across all 33

2009 Stroke Controlled trial quality: predicted high

3. Ropinirole

Ropinirole Top results for ropinirole - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ropinirole The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

4. A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome. (Abstract)

A mixed treatment comparison of gabapentin enacarbil, pramipexole, ropinirole and rotigotine in moderate-to-severe restless legs syndrome. A mixed treatment comparison (MTC) was performed to investigate the relative efficacy and safety of licensed pharmaceuticals for moderate-to-severe restless legs syndrome (RLS).RLS trials published over the past 10 years were identified via systematic literature searches of MEDLINE, Embase, Cochrane CENTRAL, and manufacturers' websites. MTC was performed (...) with WinBUGS software using a Bayesian approach. Identified primary outcomes: change in International RLS Study Group Rating Scale (IRLS) at week 12 and end of maintenance (EoM).IRLS and Clinical Global Impression - Improvement Scale (CGI-I) responders, RLS-6 items and adverse events (AEs).Twenty-eight clinical trials were identified. Fifteen were included in the primary analysis. Indirect comparisons were established among gabapentin enacarbil, pramipexole, ropinirole, rotigotine and placebo. Overall

2014 Current medical research and opinion

5. Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD

Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03708237 Recruitment Status

2018 Clinical Trials

6. Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis

Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Ropinirole (...) Party): Michael K. Porayko, M.D., Vanderbilt University Medical Center Study Details Study Description Go to Brief Summary: The investigator's aim is to compare the efficacy of Ropinirole (Requip) to vitamin E in the treatment of muscle cramps in cirrhotic patients. Condition or disease Intervention/treatment Phase Muscle Cramp Cirrhosis Drug: Vitamin E Drug: Ropinirole Other: Muscle cramp survey Phase 4 Detailed Description: Muscle cramps are common in liver disease, especially in patients

2017 Clinical Trials

7. Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. (Abstract)

Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. Recently, the US Food and Drug Administration issued a warning regarding the potential risk of gambling disorder, but large epidemiologic studies are lacking.We used a large health claims database from the United States and conducted a nested case-control study. Cases were defined as subjects newly diagnosed with gambling disorder or impulse control disorder (...) ) and impulse control disorder (RR, 7.71; 95% CI, 5.81-10.34). The risk was also elevated for pramipexole or ropinirole for both gambling disorder and impulse control disorder (RR, 7.61; 95% CI, 2.75-21.07; RR, 3.28; 95% CI, 2.31-4.66, respectively).Our study confirms an association between aripiprazole, pramipexole, or ropinirole and impulse control disorder and gambling disorder.

2016 Journal of Clinical Psychopharmacology

8. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Full Text available with Trip Pro

Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Amyotrophic lateral sclerosis (ALS) is an intractable and incurable neurological disease. It is a progressive disease characterized by muscle atrophy and weakness caused by selective vulnerability of upper and lower motor neurons. In disease research, it has been common to use mouse (...) models carrying mutations in responsible genes for familial ALS as pathological models of ALS. However, there is no model that has reproduced the actual conditions of human spinal cord pathology. Thus, we developed a method of producing human spinal motor neurons using human induced pluripotent stem cells (iPSCs) and an innovative experimental technique for drug screening. As a result, ropinirole hydrochloride was eventually discovered after considering such results as its preferable transitivity

2019 Regenerative Therapy Controlled trial quality: predicted high

9. Ropinirole in the treatment of restless legs syndrome. (Abstract)

Ropinirole in the treatment of restless legs syndrome. 15743551 2005 06 02 2018 11 13 1528-4042 5 2 2005 Mar Current neurology and neuroscience reports Curr Neurol Neurosci Rep Ropinirole in the treatment of restless legs syndrome. 137-9 Thorpy Michael M eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States Curr Neurol Neurosci Rep 100931790 1528-4042 0 Indoles 030PYR8953 ropinirole IM Adolescent Adult Aged Double-Blind Method Humans Indoles therapeutic

2005 Current neurology and neuroscience reports Controlled trial quality: uncertain

10. A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. (Abstract)

A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. 8615176 1996 05 31 2013 11 21 0091-3952 69 1996 Advances in neurology Adv Neurol A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients. 531-4 Rascol O O Service de Pharmacologie Médicale et Clinique, INSERM U317, Faculté de Médecine, Toulouse, France. Lees A J AJ Senard J M (...) JM Pirtosek Z Z Brefel C C Montastruc J L JL Fuell D D eng Clinical Trial Journal Article Randomized Controlled Trial United States Adv Neurol 0367524 0091-3952 0 Antiparkinson Agents 0 Dopamine Agonists 0 Indoles 0 Receptors, Dopamine D2 030PYR8953 ropinirole 46627O600J Levodopa IM Antiparkinson Agents administration & dosage adverse effects therapeutic use Dopamine Agonists administration & dosage adverse effects therapeutic use Drug Therapy, Combination Humans Indoles administration & dosage

1996 Advances in Neurology Controlled trial quality: uncertain

11. Ropinirole versus placebo in primary restless legs syndrome. (Abstract)

Ropinirole versus placebo in primary restless legs syndrome. 16858879 2006 08 29 2018 11 13 1528-4042 6 4 2006 Jul Current neurology and neuroscience reports Curr Neurol Neurosci Rep Ropinirole versus placebo in primary restless legs syndrome. 278-80 Morgan John C JC Sethi Kapil D KD eng Journal Article United States Curr Neurol Neurosci Rep 100931790 1528-4042 2006 7 25 9 0 2006 7 25 9 1 2006 7 25 9 0 ppublish 16858879 Ann Neurol. 1982 Jan;11(1):41-7 6460467 Mayo Clin Proc. 2006 Jan;81(1):17

2006 Current neurology and neuroscience reports Controlled trial quality: uncertain

12. Ropinirole versus levodopa in Parkinson's disease. (Abstract)

Ropinirole versus levodopa in Parkinson's disease. 15217540 2004 09 10 2018 11 13 1528-4042 4 4 2004 Jul Current neurology and neuroscience reports Curr Neurol Neurosci Rep Ropinirole versus levodopa in Parkinson's disease. 274-6 Morgan John C JC Sethi Kapil D KD eng Clinical Trial Comparative Study Journal Article Multicenter Study Randomized Controlled Trial United States Curr Neurol Neurosci Rep 100931790 1528-4042 0 Indoles 030PYR8953 ropinirole 46627O600J Levodopa IM Adult Aged Double

2004 Current neurology and neuroscience reports Controlled trial quality: uncertain

13. Do dopaminergic agents increase the daytime sleep propensity? Article reviewed: Effect of ropinirole on sleep onset. A randomized, placebo-controlled study in healthy volunteers. (Abstract)

Do dopaminergic agents increase the daytime sleep propensity? Article reviewed: Effect of ropinirole on sleep onset. A randomized, placebo-controlled study in healthy volunteers. 14592182 2003 12 10 2003 10 31 1389-9457 3 5 2002 Sep Sleep medicine Sleep Med. Do dopaminergic agents increase the daytime sleep propensity? Article reviewed: Effect of ropinirole on sleep onset. A randomized, placebo-controlled study in healthy volunteers. 445-6 Zucconi Marco M Department of Neurology, Sleep

2003 Sleep medicine Controlled trial quality: uncertain

14. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. Full Text available with Trip Pro

Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. 1683897 1992 01 14 2018 11 13 0022-3050 54 10 1991 Oct Journal of neurology, neurosurgery, and psychiatry J. Neurol. Neurosurg. Psychiatry Ropinirole (SK and F 101468) in the treatment of Parkinson's disease. 938 Kleedorfer B B Stern G M GM Lees A J AJ Bottomley J M JM Sree-Haran N N eng Comparative Study Letter England J Neurol Neurosurg Psychiatry 2985191R 0022-3050 0 Dopamine Agents 0 Indoles 030PYR8953 ropinirole

1991 Journal of neurology, neurosurgery, and psychiatry

15. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. Full Text available with Trip Pro

Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study. To confirm the superiority of transdermal rotigotine up to 16 mg/24 h over placebo, and non-inferiority to ropinirole, in Japanese Parkinson's disease (PD) patients on concomitant levodopa therapy.This trial was a randomized, double-blind, double-dummy, three-arm parallel group placebo- and ropinirole-controlled trial. Four-hundred and twenty PD patients whose motor symptoms were not well controlled (...) by levodopa treatment were randomized 2:2:1 to receive rotigotine, ropinirole (up to 15 mg/day) or placebo during a 16-week treatment period followed by a 4-week taper period. The primary variable was change in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III (ON state) sum score from baseline to the end of the treatment period.The difference in the change in the UPDRS Part III (ON state) sum score from baseline to the end of treatment between rotigotine and placebo groups was -6.4 ± 1.2 (95

2015 Parkinsonism & related disorders Controlled trial quality: predicted high

16. Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type

Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00639119 Recruitment Status : Unknown Verified February 2008 by University of Turku. Recruitment status was: Enrolling

2008 Clinical Trials

17. Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafil

Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafil Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration (...) and Haemodiafiltration) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated

2009 Clinical Trials

18. A Case of Ropinirole-Induced Compulsive Behavior Full Text available with Trip Pro

A Case of Ropinirole-Induced Compulsive Behavior 23469324 2013 06 04 2018 11 13 2155-7772 14 5 2012 The primary care companion for CNS disorders Prim Care Companion CNS Disord A case of ropinirole-induced compulsive behavior. 10.4088/PCC.12l01390 PCC.12l01390 Singh Harmit H Department of Psychiatry, University of Nebraska Medical Center/Creighton University, Omaha, Nebraska, USA. Veglia Mary Theresa MT Ramaswamy Sriram S eng Journal Article 2012 10 11 United States Prim Care Companion CNS

2012 The Primary Care Companion for CNS Disorders

19. Ropinirole

Ropinirole Ropinirole Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Ropinirole Ropinirole Aka: Ropinirole , Requip II. Indications (...) (rare at low dose) s (related to receptor agonist activity, D3) Hypersexuality Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Ropinirole." Click on the image (or right click) to open the source website in a new browser window. Related Studies (from Trip Database) Cost: Medications ropinirole (on 5/17/2017 at ) ROPINIROLE HCL 0.25 MG TABLET Generic $0.09 each ROPINIROLE HCL 0.5 MG TABLET Generic $0.07 each ROPINIROLE HCL 1 MG

2018 FP Notebook

20. Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease. Full Text available with Trip Pro

Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease. Ropinirole prolonged release (RPR) is a once-daily formulation. However, there may be individual pharmacokinetic differences so that multiple dosing may be preferred in some individuals. This study compares once-daily and twice-daily RPR in patients with Parkinson's disease.This study was an open-label crossover study. We enrolled Parkinson's disease patients on dopamine agonist

2013 BMC Neurology